4//SEC Filing
Bratton Capital Inc. 4
Accession 0000899243-19-010426
CIK 0001714899other
Filed
Apr 8, 8:00 PM ET
Accepted
Apr 9, 9:27 PM ET
Size
13.5 KB
Accession
0000899243-19-010426
Insider Transaction Report
Form 4
BRATTON DOUGLAS K
10% Owner
Transactions
- Other
Common Stock
2019-03-25−158,764→ 953,035 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 19,462,499(indirect: By AKDL, L.P.)
Common Stock
Bratton Capital Management, L.P.
10% Owner
Transactions
- Other
Common Stock
2019-03-25−158,764→ 953,035 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 19,462,499(indirect: By AKDL, L.P.)
Common Stock
Neuro Line Partners LP
10% Owner
Transactions
- Other
Common Stock
2019-03-25−158,764→ 953,035 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 19,462,499(indirect: By AKDL, L.P.)
Common Stock
Bratton Capital Inc.
10% Owner
Transactions
- Other
Common Stock
2019-03-25−158,764→ 953,035 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 19,462,499(indirect: By AKDL, L.P.)
Common Stock
Footnotes (5)
- [F1]Pro rata in-kind distribution of shares of common stock, par value $0.01 per share, (the "Common Stock") of Denali Therapeutics Inc. from Neuro Line Partners, L.P. ("Neuro Line") to limited partners of Neuro Line without consideration.
- [F2]The shares of Common Stock reported in Column 5 are held directly by Neuro Line. The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.
- [F3](Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
- [F4]These shares of Common Stock reported in Column 5 are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.
- [F5](Continued from Footnote 4) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
Documents
Issuer
Denali Therapeutics Inc.
CIK 0001714899
Entity typeother
IncorporatedTX
Related Parties
1- filerCIK 0001723783
Filing Metadata
- Form type
- 4
- Filed
- Apr 8, 8:00 PM ET
- Accepted
- Apr 9, 9:27 PM ET
- Size
- 13.5 KB